Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
821.46
-2.16 (-0.26%)
May 5, 2025, 4:00 PM EDT - Market closed
Eli Lilly Revenue
Eli Lilly had revenue of $12.73B in the quarter ending March 31, 2025, with 45.17% growth. This brings the company's revenue in the last twelve months to $49.00B, up 36.38% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$49.00B
Revenue Growth
+36.38%
P/S Ratio
15.13
Revenue / Employee
$1,042,621
Employees
47,000
Market Cap
737.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.19B |
Thermo Fisher Scientific | 42.90B |
Abbott Laboratories | 42.34B |
LLY News
- 2 hours ago - Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms - CNBC
- 6 hours ago - Lilly declares second-quarter 2025 dividend - PRNewsWire
- 1 day ago - Top 50 High-Quality Dividend Stocks For May 2025 - Seeking Alpha
- 2 days ago - Eli Lilly's Meltdown Triggers Near Doubling Upside Potential - Reiterate Buy - Seeking Alpha
- 2 days ago - Eli Lilly: Don't Overthink This Buying Opportunity - Seeking Alpha
- 3 days ago - Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say - Benzinga
- 3 days ago - Eli Lilly's Stock Selloff Is Overdone, Analysts Say. Here's Why. - Barrons
- 3 days ago - Lilly to participate in Bank of America Securities 2025 Healthcare Conference - PRNewsWire